Ted Karkus - ProPhase Labs Chairman and CEO
PRPH Stock | USD 0.44 0.11 33.33% |
Chairman
Mr. Ted William Karkus is a Chairman of the Board, Chief Executive Officer of the Company. Mr. KARKUS was the Chairman of the Board and the Chief Executive Officer of the Company since June 2009. Mr. Karkus was formerly the managing member of Forrester Financial, LLC, a management consulting firm founded by Mr. Karkus in 2001. Forrester Financial LLC provided a wide range of services to emerginggrowth companies, including the structuring and raising of working capital as well as assisting management in developing operational, marketing and financial strategies. Mr. Karkus was instrumental in assisting the turnaround of ID Biomedical, an influenza vaccine manufacturer, which in 2005 was sold to GlaxoSmithKline plc for over 1.4 billion. Mr. Karkus has twentyfive years of experience in securities and capital markets including two years with Fahnestock Co. Inc. a fullservice brokerage firm, where he was Senior Vice President, Director of Institutional Equities, and four years at S.G. Warburg, an investment bank, where he was an institutional equity salesman and developed a large network of institutional investors. Mr. Karkus graduated with an MBA from Columbia University Graduate School of Business in 1984 where he received Beta Gamma Sigma honors. He graduated Magna Cum Laude from Tufts University in 1981. Mr. Karkus brings extensive financial structuring as well as operational and marketing strategy experience to our Board, including successful restructuring and turnaround scenarios in the pharmaceutical industry. These skills, as well as Mr. Karkus experience as our Chairman and Chief Executive Officer, along with his deep knowledge of and genuine interest in our Company, management skills and business savvy, and his performance as a Board member of the Company, led the Board to conclude that he should be nominated to serve another term as a director. since 2009.
Age | 66 |
Tenure | 16 years |
Professional Marks | MBA |
Address | 711 Stewart Avenue, Garden City, NY, United States, 11530 |
Phone | 215 345 0919 |
Web | https://www.prophaselabs.com |
Ted Karkus Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ted Karkus against ProPhase Labs stock is an integral part of due diligence when investing in ProPhase Labs. Ted Karkus insider activity provides valuable insight into whether ProPhase Labs is net buyers or sellers over its current business cycle. Note, ProPhase Labs insiders must abide by specific rules, including filing SEC forms every time they buy or sell ProPhase Labs'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ted Karkus over a week ago Disposition of 100000 shares by Ted Karkus of ProPhase Labs subject to Rule 16b-3 | ||
Ted Karkus over six months ago Disposition of 400000 shares by Ted Karkus of ProPhase Labs at 6.0 subject to Rule 16b-3 | ||
Ted Karkus over a year ago Bona fide gift to Ted Karkus of 50000 shares of ProPhase Labs subject to Section 16 | ||
Ted Karkus over a year ago Bona fide gift to Ted Karkus of 100000 shares of ProPhase Labs subject to Section 16 |
ProPhase Labs Management Efficiency
The company has return on total asset (ROA) of (0.2412) % which means that it has lost $0.2412 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5871) %, meaning that it created substantial loss on money invested by shareholders. ProPhase Labs' management efficiency ratios could be used to measure how well ProPhase Labs manages its routine affairs as well as how well it operates its assets and liabilities. The ProPhase Labs' current Return On Tangible Assets is estimated to increase to -0.19. The ProPhase Labs' current Return On Capital Employed is estimated to increase to -0.33. As of now, ProPhase Labs' Other Current Assets are decreasing as compared to previous years. The ProPhase Labs' current Intangible Assets is estimated to increase to about 14.9 M, while Total Current Assets are projected to decrease to under 27.5 M.ProPhase Labs currently holds 21.38 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. ProPhase Labs has a current ratio of 4.12, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ProPhase Labs' use of debt, we should always consider it together with its cash and equity.
Similar Executives
Found 2 records | CHAIRMAN Age | ||
Elazar Rabbani | Enzo Biochem | 81 | |
Erez Raphael | DarioHealth Corp | 52 |
Management Performance
Return On Equity | -0.59 | ||||
Return On Asset | -0.24 |
ProPhase Labs Leadership Team
Elected by the shareholders, the ProPhase Labs' board of directors comprises two types of representatives: ProPhase Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ProPhase. The board's role is to monitor ProPhase Labs' management team and ensure that shareholders' interests are well served. ProPhase Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ProPhase Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
Billy White, Consultant | ||
Lance Bisesar, Corporate Controller | ||
Robert Morse, Principal Controller | ||
Ted Karkus, Chairman and CEO | ||
Sergio Miralles, Executive Diagnostics | ||
Kamal Obbad, Senior Genomics | ||
Jason Karkus, President Diagnostics | ||
Monica Brady, Principal Financial Officer & Principal Accounting Officer | ||
Jed Latkin, Chief Department | ||
Alice Lioi, EVP BioPharma |
ProPhase Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ProPhase Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.59 | ||||
Return On Asset | -0.24 | ||||
Profit Margin | (2.18) % | ||||
Operating Margin | (2.52) % | ||||
Current Valuation | 38.91 M | ||||
Shares Outstanding | 30.23 M | ||||
Shares Owned By Insiders | 11.15 % | ||||
Shares Owned By Institutions | 8.31 % | ||||
Number Of Shares Shorted | 84.87 K | ||||
Price To Earning | 6.59 X |
Currently Active Assets on Macroaxis
When determining whether ProPhase Labs offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProPhase Labs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Prophase Labs Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Prophase Labs Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.53) | Revenue Per Share | Quarterly Revenue Growth (0.62) | Return On Assets |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.